Cardiology Clinical Trials

Explore our current clinical trials for cardiology:

[Updated: 10/26/21]

Cardiovascular

PROACT Xa

Status:
Enrolling

Summary:
A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban

Description:
A prospective, randomized, active (warfarin) controlled, parallel-arm clinical trial to determine if patients with an On-X aortic valve can be maintained safely and effectively on the factor Xa inhibitor apixaban.

Electrophysiology

AMPLATZER™ Amulet™ LAA Occluder Trial

Status:
Active, in follow-up

Description:
The AMPLATZER™ Amulet™ Left Atrial Appendage (LAA) Occluder Trial is designed to evaluate the safety and effectiveness of the Amulet device compared to the approved WATCHMAN LAA closure device in patients with non-valvular atrial fibrillation and at a high risk for bleeding. Eligible patients will be randomized to receive either the Amulet device or the WATCHMAN device.

Heart Failure

ALN-TTR02-012

Status:
Active, in follow-up

Summary:
A Phase 4 Multicenter Observational Study to Evaluate Effectiveness of Patisiran in Patients with Polyneuropathy of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with a V1221 or T60A Mutation.

Description:
This study is to evaluate the effectiveness of patisiran in patients with ATTRv amyloidosis with polyneuropathy who have a V122I or T60A mutation.

ALN-TTRS02-003

Status:
Active, in follow-up

Summary:
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Description:
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Vutrisiran in patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy).

DAPA ACT HF

Status:
Enrolling

Summary:
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68

Description:
This is a multicenter, randomized, double‐blind, parallel group, placebo‐controlled trial to evaluate the effect of in‐hospital initiation of Dapagliflozin on clinical outcomes in patients with Heart Failure with reduced Ejection Fraction who have been stabilized during hospitalization for acute Heart Failure.

Scale-HF 1 (Bodyport)

Status:
Enrolling

Summary:
Surveillance and Alert-based Multiparameter Monitoring to Reduce Worsening Heart Failure Events

Description:
The overarching goal of this prospective, multicenter study is to utilize data from the Bodyport scale to develop an index that allows for the early detection of worsening heart failure (HF). The Bodyport scale is capable of measuring key HF parameters of congestion and cardiac perfusion on a regular basis in a patient’s home. These data will be combined into a composite index that may be used to identify patients at increased risk for decompensation, inform the reason for their decline, and offer the possibility to remotely optimize therapy to prevent further worsening HF.

V-Wave RELIEVE

Status
Enrolling

Summary
Reducing Lung CongestIon Symptoms in Advanced Heart Failure (RELIEVE-HF)

Description
This is a prospective, multi-center, 1:1 randomized, patient and observer blinded clinical study, with a Shunt Treatment arm and a non-implant Control arm. The study device, the V-Wave Interartrial Shunt System, includes a permanent implant – the Shunt. The Shunt is placed during a minimally invasive cardiac catheterization procedure using its dedicated Delivery Catheter. By transferring blood from the left to the right atrium, the Shunt is intended to reduce excessive left-sided cardiac filling pressures in patients with advanced Heart Failure.

Interventional

AEGIS-II

Status:
Enrolling

Summary:
Study to Investigate the Efficacy & Safety of CSL112 in Subjects With Acute Coronary Syndrome

Description:
CSL112 is indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in acute coronary syndrome (ACS) patients diagnosed with either ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation.

Disrupt PAD III

Status:
Active, in follow-up

Summary:
Shockwave Medical Peripheral Lithoplasty System Study for PAD

Description:
This study is a multi-center, single blind, randomized (1:1) study of Lithoplasty treatment used in combination with DCB versus standard balloon angioplasty used in combination with DCB to treat moderate and severely calcified femoropopliteal arteries.

ECLIPSE Study

Status:
Enrolling

Summary:
Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts

Description:
This trial will evaluate Orbital Atherectomy compared to conventional balloon angioplasty technique for the treatment of severely calcified lesions prior to implantation of drug-eluting stents (DES).

HARMONEE Study

Status:
Active, in follow-up

Summary:
Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich’s Combo StEnt (HARMONEE)

Description:
This study is a multi-center, single-blind, randomized, clinical evaluation of the Combination Sirolimus-Eluting and anti-CD34 Antibody-Coated (COMBO) Stent for Coronary Lesions.

North American COVID-19 ST-Segment Elevation Myocardial Infarction (NACMI)

Status:
Active

Description:
The proposed registry will utilize retrospective and prospective observational methods to assess and compare the characteristics, treatment, and follow-up of confirmed or suspected COVID-19 adult (age ≥ 18 years old) patients presenting with ST segment elevation.

TRANSCEND Study

Status:
Active, in follow-up

Summary:
Safety and Efficacy of the SurVeil™ Drug-Coated Balloon (DCB)

Description:
This study is to demonstrate the safety & efficacy of the SurVeil DCB for treatment of subjects with symptomatic peripheral artery disease (PAD) due to stenosis of the femoral and/or popliteal arteries.

AMPLATZER™ PFO Occluder Post Approval Study

Status:
Enrolling

Description:
The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post approval setting.

DEFINE GPS

Status:
Enrolling

Summary:
The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Distal Evaluation of Functional Performance With Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting

Description:
The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post approval settinThis multi-center, prospective, randomized controlled study compares PCI guided by angiography versus iFR Co-Registration using commercially available Philips pressure guidewires and the SyncVision co-registration system.